SCOPUS 정보 검색 플랫폼

Nature Reviews Nephrology

Volumn 9, Issue 9, 2013, Pages 495-496

Thrombotic microangiopathy: Eculizumab for atypical haemolytic uraemic syndrome: What next?

(2) Fakhouri, Fadi a Frémeaux Bacchi, Véronique b

a UNIVERSITÉ DE NANTES (France)

b HÔPITAL EUROPÉEN GEORGES POMPIDOU (France)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; MONOCLONAL ANTIBODY;

HEMOLYTIC UREMIC SYNDROME; HEMOLYTIC-UREMIC SYNDROME; HUMAN; REVIEW; THROMBOTIC MICROANGIOPATHIES; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; HEMOLYTIC-UREMIC SYNDROME; HUMANS; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84900266732 PISSN: 17595061 EISSN: 1759507X Source Type: Journal
DOI: 10.1038/nrneph.2013.150 Document Type: Article

Times cited : (8)

References (8)

1
- 84876044818
- Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults
- Fremeaux-Bacchi, V. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol. 8, 554–562 (2013).
- (2013) Clin. J. Am. Soc. Nephrol , vol.8 , pp. 554-562
- Fremeaux-Bacchi, V.¹

2
- 84874417661
- Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome
- Le Quintrec, M. et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am. J.Transplant. 13, 663–675 (2013).
- (2013) Am. J.Transplant , vol.13 , pp. 663-675
- Le Quintrec, M.¹

3
- 84867993256
- Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
- Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C. & Fremeaux-Bacchi, V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat. Rev. Nephrol. 8, 643–657 (2012).
- (2012) Nat. Rev. Nephrol , vol.8 , pp. 643-657
- Zuber, J.¹ Fakhouri, F.² Roumenina, L.T.³ Loirat, C.⁴ Fremeaux-Bacchi, V.⁵

4
- 84875242693
- [online]
- Electronic Medicines Compendium. Soliris—Summary of Product Characteristics [online], http://www.medicines.org.uk/emc/medicine/19966/SPC/soliris/(2012).
- (2012) Soliris—Summary of Product Characteristics

5
- 79960720836
- [online], http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf
- U. S. Food and Drug Administration. Highlights of Prescribing Information: Soliris [online], http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf (2011).
- (2011) Highlights of Prescribing Information: Soliris

6
- 84878589219
- Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome
- Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169–2181 (2013).
- (2013) N. Engl. J. Med , vol.368 , pp. 2169-2181
- Legendre, C.M.¹

7
- 85028123672
- Efficacy of eculizumab in atypical hemolytic uremic syndrome with or without prior transplant [MP 034]. Poster at the ERA-EDTA meeting, Istanbul, Turkey
- Legendre, C. M. et al. Efficacy of eculizumab in atypical hemolytic uremic syndrome with or without prior transplant [MP 034]. Poster at the ERA-EDTA meeting, Istanbul, Turkey, May 18–21 2013.
- (2013) May , pp. 18-21
- Legendre, C.M.¹

8
- 84865692008
- [online], http://clinicaltrials.gov/ct2/show/NCT01194973?term=eculizumab&rank=29
- US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01194973?term=eculizumab&rank=29 (2012).
- (2012) Clinicaltrials.Gov

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.